TransMedics Group (TMDX) Financials

$121.84 -2.88 (-2.31%)

As of 03:49 PM Eastern

Annual Income Statements for TransMedics Group

This table shows TransMedics Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/28/2019
Net Income / (Loss) Attributable to Common Shareholders	35	-25	-36	-44	-29	-34
Consolidated Net Income / (Loss)	35	-25	-36	-44	-29	-34
Net Income / (Loss) Continuing Operations	35	-25	-36	-44	-29	-34
Total Pre-Tax Income	36	-27	-36	-44	-29	-34
Total Operating Income	37	-29	-31	-39	-26	-30
Total Gross Profit	262	154	65	21	17	14
Total Revenue	442	242	93	30	26	24
Operating Revenue	442	242	93	30	26	24
Total Cost of Revenue	179	88	28	9.10	9.00	9.74
Operating Cost of Revenue	179	88	28	9.10	9.00	9.74
Total Operating Expenses	225	183	97	61	43	43
Selling, General & Admin Expense	169	120	70	38	24	24
Research & Development Expense	56	63	27	22	19	20
Total Other Income / (Expense), net	-1.72	2.06	-4.73	-4.75	-2.33	-3.90
Interest Expense	14	11	3.73	3.87	3.99	4.35
Other Income / (Expense), net	13	13	-1.00	-0.88	1.65	0.45
Income Tax Expense	0.32	-1.64	0.07	0.04	0.03	0.04
Basic Earnings per Share	$1.07	($0.77)	($1.23)	($1.60)	($1.16)	($2.36)
Weighted Average Basic Shares Outstanding	33.23M	32.52M	29.56M	27.62M	24.70M	14.20M
Diluted Earnings per Share	$1.01	($0.77)	($1.23)	($1.60)	($1.16)	($2.36)
Weighted Average Diluted Shares Outstanding	35.22M	32.52M	29.56M	27.62M	24.70M	14.20M
Weighted Average Basic & Diluted Shares Outstanding	33.66M	32.72M	32.20M	27.96M	24.70M	14.20M
Cash Dividends to Common per Share	$0.00	$0.00	-	$0.00	$0.00	$0.00

This table shows TransMedics Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	26	6.86	4.22	12	12	4.03	-25	-1.00	-2.64	-6.72	-7.43
Consolidated Net Income / (Loss)	26	6.86	4.22	12	12	4.03	-25	-1.00	-2.64	-6.72	-7.43
Net Income / (Loss) Continuing Operations	26	6.86	4.22	12	12	4.03	-25	-1.00	-2.64	-6.72	-7.43
Total Pre-Tax Income	27	6.99	4.25	12	12	3.86	-27	-0.98	-2.63	-6.70	-7.41
Total Operating Income	27	8.64	3.92	13	12	2.60	-28	-0.91	-2.09	-6.78	-5.54
Total Gross Profit	88	72	61	69	60	48	41	37	29	21	18
Total Revenue	144	122	109	114	97	81	66	52	42	31	26
Operating Revenue	144	122	109	114	97	81	66	52	42	31	26
Total Cost of Revenue	55	50	48	45	37	33	26	16	13	11	7.57
Operating Cost of Revenue	55	50	48	45	37	33	26	16	13	11	7.57
Total Operating Expenses	61	63	57	57	48	45	69	38	31	27	24
Selling, General & Admin Expense	44	47	43	43	36	35	31	29	25	22	17
Research & Development Expense	17	16	14	14	11	11	38	8.29	5.87	5.76	6.81
Total Other Income / (Expense), net	-0.77	-1.66	0.32	-0.36	-0.03	1.26	1.41	-0.07	-0.54	0.08	-1.86
Interest Expense	3.46	3.57	3.62	3.62	3.60	3.61	3.59	2.51	1.09	1.01	0.79
Other Income / (Expense), net	2.69	1.92	3.94	3.27	3.57	4.87	5.00	2.43	0.56	1.09	-1.08
Income Tax Expense	0.99	0.13	0.03	-0.04	0.20	-0.17	-1.51	0.02	0.01	0.02	0.02
Basic Earnings per Share	$0.76	$0.20	$0.13	$0.37	$0.37	$0.12	($0.78)	($0.03)	($0.08)	($0.19)	($0.25)
Weighted Average Basic Shares Outstanding	33.72M	33.23M	33.44M	33.12M	32.76M	32.52M	32.61M	32.55M	32.26M	29.56M	30.23M
Diluted Earnings per Share	$0.70	$0.19	$0.12	$0.35	$0.35	$0.12	($0.78)	($0.03)	($0.08)	($0.19)	($0.25)
Weighted Average Diluted Shares Outstanding	39.91M	35.22M	35.68M	35.29M	34.68M	32.52M	32.61M	32.55M	32.26M	29.56M	30.23M
Weighted Average Basic & Diluted Shares Outstanding	33.83M	33.66M	33.56M	33.36M	32.94M	32.72M	32.65M	32.63M	32.55M	32.20M	31.92M

This table details how cash moves in and out of TransMedics Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/28/2019
Net Change in Cash & Equivalents	-58	194	176	1.00	4.49	-0.06
Net Cash From Operating Activities	49	-13	-46	-29	-30	-32
Net Cash From Continuing Operating Activities	49	-13	-46	-29	-30	-32
Net Income / (Loss) Continuing Operations	35	-25	-36	-44	-29	-34
Consolidated Net Income / (Loss)	35	-25	-36	-44	-29	-34
Depreciation Expense	20	8.18	3.48	1.82	1.58	1.22
Amortization Expense	0.00	0.00	0.38	1.36	0.63	-0.21
Non-Cash Adjustments To Reconcile Net Income	39	50	13	9.18	1.86	1.87
Changes in Operating Assets and Liabilities, net	-45	-46	-27	3.00	-5.59	-1.63
Net Cash From Investing Activities	-129	-194	55	29	-42	-61
Net Cash From Continuing Investing Activities	-129	-194	55	29	-42	-61
Purchase of Property, Plant & Equipment	-130	-152	-12	-3.52	-0.46	-0.17
Acquisitions	0.44	-42	0.00	0.00	-	-
Purchase of Investments	0.00	0.00	-10	-72	-122	-82
Sale and/or Maturity of Investments	0.00	0.00	77	105	81	22
Net Cash From Financing Activities	23	400	168	1.39	76	93
Net Cash From Continuing Financing Activities	23	400	168	1.39	76	93
Repayment of Debt	0.00	0.00	-36	0.00	-2.25	0.00
Repurchase of Common Equity	0.00	0.00	0.00	0.00	0.00	-4.85
Issuance of Debt	0.00	445	59	0.00	0.00	-
Issuance of Common Equity	2.06	0.96	140	0.42	75	97
Other Financing Activities, net	21	-46	5.11	0.97	2.48	0.20
Effect of Exchange Rate Changes	-0.54	0.19	-1.02	-0.80	0.80	-
Cash Interest Paid	11	8.09	3.26	3.33	3.48	3.88

This table details how cash moves in and out of TransMedics Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-27	6.56	-33	13	-45	-32	-155	387	-5.56	-3.28	174
Net Cash From Operating Activities	-2.86	20	6.86	26	-3.44	8.30	-6.87	-5.80	-8.66	-4.04	-14
Net Cash From Continuing Operating Activities	-2.86	20	6.86	26	-3.44	8.30	-6.87	-5.80	-8.66	-4.04	-14
Net Income / (Loss) Continuing Operations	26	6.86	4.22	12	12	4.03	-25	-1.00	-2.64	-6.72	-7.43
Consolidated Net Income / (Loss)	26	6.86	4.22	12	12	4.03	-25	-1.00	-2.64	-6.72	-7.43
Depreciation Expense	6.14	5.68	5.18	4.60	4.30	3.61	1.89	1.39	1.29	1.29	0.89
Non-Cash Adjustments To Reconcile Net Income	9.73	13	8.71	8.75	8.16	6.35	34	5.66	4.08	2.73	4.30
Changes in Operating Assets and Liabilities, net	-44	-5.83	-11	0.18	-28	-5.68	-17	-12	-11	-1.33	-12
Net Cash From Investing Activities	-27	-14	-48	-24	-44	-42	-150	-1.38	-0.93	-2.76	25
Net Cash From Continuing Investing Activities	-27	-14	-48	-24	-44	-42	-150	-1.38	-0.93	-2.76	25
Purchase of Property, Plant & Equipment	-27	-14	-48	-24	-44	-42	-108	-1.38	-0.93	-2.76	-2.93
Net Cash From Financing Activities	3.03	1.19	7.86	11	3.19	0.92	1.52	394	3.96	3.07	164
Net Cash From Continuing Financing Activities	3.03	1.19	7.86	11	3.19	0.92	1.52	394	3.96	3.07	164
Issuance of Debt	0.00	-	-	-	0.00	-	-	445	0.00	59	-
Issuance of Common Equity	1.29	-	1.42	-	0.64	-	0.57	-	0.38	-0.16	140
Other Financing Activities, net	1.74	1.19	6.44	11	2.55	0.92	0.95	-51	3.57	3.23	1.44
Effect of Exchange Rate Changes	0.36	-0.69	0.39	-0.06	-0.17	0.29	-0.18	0.01	0.07	0.45	-0.61

This table presents TransMedics Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/28/2019	12/29/2018
Total Assets	804	706	277	135	152	105	42
Total Current Assets	497	511	252	119	147	100	35
Cash & Equivalents	337	395	201	26	25	20	20
Accounts Receivable	98	64	28	5.93	6.86	6.56	3.44
Inventories, net	47	44	21	15	12	11	9.28
Prepaid Expenses	16	8.03	2.90	5.46	2.33	1.54	1.84
Plant, Property, & Equipment, net	286	174	19	9.84	4.75	4.79	3.47
Total Noncurrent Assets	21	21	5.63	6.35	0.51	0.51	3.89
Goodwill	12	12	0.00	-	-	-	-
Intangible Assets	2.15	2.35	0.00	-	-	-	-
Other Noncurrent Operating Assets	7.19	7.11	5.63	6.35	0.51	0.51	3.89
Total Liabilities & Shareholders' Equity	804	706	277	135	152	105	42
Total Liabilities	575	569	90	67	48	51	48
Total Current Liabilities	60	55	24	23	12	16	13
Accounts Payable	10	13	3.34	6.65	1.21	7.25	4.72
Accrued Expenses	45	38	19	16	10	8.33	7.18
Current Deferred Revenue	1.74	1.96	0.24	0.25	0.26	0.54	0.66
Other Current Liabilities	2.73	2.04	1.44	0.00	-	-	-
Total Noncurrent Liabilities	516	514	66	44	36	35	35
Long-Term Debt	509	506	59	35	35	34	34
Other Noncurrent Operating Liabilities	6.25	7.71	7.42	8.60	-	-	0.90
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	229	137	187	68	104	55	-192
Total Preferred & Common Equity	229	137	187	68	104	55	-192
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Common Equity	229	137	187	68	104	55	-192
Common Stock	697	641	666	510	502	424	144
Retained Earnings	-468	-504	-479	-442	-398	-369	-336
Accumulated Other Comprehensive Income / (Loss)	-0.36	-0.20	-0.23	-0.19	-0.10	-0.00	-0.10

This table presents TransMedics Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	838	786	759	724	689	690	287	275
Total Current Assets	506	492	509	488	537	663	262	251
Cash & Equivalents	310	330	363	350	427	582	195	204
Accounts Receivable	142	90	81	82	61	48	39	22
Inventories, net	43	52	49	49	39	31	24	19
Prepaid Expenses	10	20	17	7.61	9.60	2.38	3.77	5.51
Plant, Property, & Equipment, net	311	272	229	214	131	20	19	18
Total Noncurrent Assets	20	21	20	21	21	7.74	6.20	5.32
Goodwill	12	12	12	12	12	-	-	-
Intangible Assets	2.10	2.20	2.25	2.30	2.41	-	-	-
Other Noncurrent Operating Assets	6.72	7.61	6.48	6.81	7.42	7.74	6.20	5.32
Total Liabilities & Shareholders' Equity	838	786	759	724	689	690	287	275
Total Liabilities	571	576	569	564	563	545	94	87
Total Current Liabilities	56	60	54	50	49	32	29	21
Accounts Payable	11	13	13	9.23	13	7.03	4.33	3.08
Accrued Expenses	40	42	38	37	32	23	23	16
Current Deferred Revenue	2.08	2.18	1.45	2.06	2.63	0.24	0.24	0.23
Other Current Liabilities	2.79	2.54	2.14	2.09	1.99	1.88	1.48	1.41
Total Noncurrent Liabilities	516	516	514	514	514	513	66	66
Long-Term Debt	510	509	508	507	505	505	59	59
Other Noncurrent Operating Liabilities	5.52	7.07	6.60	7.16	8.23	8.46	7.03	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	266	210	190	159	126	145	193	188
Total Preferred & Common Equity	266	210	190	159	126	145	193	188
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	266	210	190	159	126	145	193	188
Common Stock	709	685	669	651	634	628	674	660
Retained Earnings	-443	-475	-479	-492	-508	-482	-481	-472
Accumulated Other Comprehensive Income / (Loss)	-0.33	-0.23	-0.24	-0.18	-0.26	-0.22	-0.22	-0.25

This table displays calculated financial ratios and metrics derived from TransMedics Group's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/28/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	82.74%	158.53%	208.83%	18.03%	8.62%	0.00%
EBITDA Growth	1,008.05%	73.05%	23.03%	-64.88%	19.96%	0.00%
EBIT Growth	416.05%	51.05%	19.52%	-62.97%	15.17%	0.00%
NOPAT Growth	284.82%	8.62%	20.27%	-49.44%	10.87%	0.00%
Net Income Growth	241.70%	30.92%	18.06%	-53.80%	14.31%	0.00%
EPS Growth	231.17%	37.40%	23.13%	-37.93%	50.85%	0.00%
Operating Cash Flow Growth	474.60%	71.57%	-58.73%	4.63%	6.26%	0.00%
Free Cash Flow Firm Growth	48.39%	-297.57%	-122.58%	-8.70%	0.00%	0.00%
Invested Capital Growth	61.41%	453.80%	323.52%	-17.88%	59.20%	0.00%
Revenue Q/Q Growth	10.09%	25.96%	30.25%	7.23%	0.00%	0.00%
EBITDA Q/Q Growth	7.98%	66.78%	18.57%	-20.65%	-1,395.74%	0.00%
EBIT Q/Q Growth	6.57%	45.32%	15.56%	-18.68%	0.00%	0.00%
NOPAT Q/Q Growth	18.21%	24.62%	12.64%	-15.98%	0.00%	0.00%
Net Income Q/Q Growth	8.66%	30.05%	14.10%	-16.79%	0.00%	0.00%
EPS Q/Q Growth	7.45%	28.70%	17.45%	-19.40%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	30.34%	48.64%	5.40%	1.67%	0.41%	0.00%
Free Cash Flow Firm Q/Q Growth	24.08%	-22.81%	11.57%	-9.08%	-428.41%	0.00%
Invested Capital Q/Q Growth	3.32%	21.39%	-8.80%	-1.42%	13.60%	-56.05%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	59.36%	63.77%	69.84%	69.92%	64.88%	58.73%
EBITDA Margin	15.84%	-3.19%	-30.58%	-122.70%	-87.83%	-119.20%
Operating Margin	8.49%	-11.89%	-33.64%	-130.29%	-102.91%	-125.42%
EBIT Margin	11.37%	-6.57%	-34.71%	-133.19%	-96.46%	-123.51%
Profit (Net Income) Margin	8.03%	-10.36%	-38.77%	-146.11%	-112.13%	-142.12%
Tax Burden Percent	99.12%	93.84%	100.18%	100.08%	100.11%	100.12%
Interest Burden Percent	71.29%	167.95%	111.49%	109.61%	116.11%	114.93%
Effective Tax Rate	0.88%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	11.44%	-13.70%	-79.32%	-234.84%	-175.78%	-255.61%
ROIC Less NNEP Spread (ROIC-NNEP)	10.24%	17.94%	-65.07%	-212.42%	-160.84%	-228.05%
Return on Net Nonoperating Assets (RNNOA)	7.95%	-1.72%	50.93%	183.35%	139.52%	194.22%
Return on Equity (ROE)	19.39%	-15.42%	-28.39%	-51.49%	-36.27%	-61.39%
Cash Return on Invested Capital (CROIC)	-35.55%	-152.52%	-202.91%	-215.21%	-221.46%	0.00%
Operating Return on Assets (OROA)	6.65%	-3.23%	-15.75%	-28.10%	-19.22%	-39.54%
Return on Assets (ROA)	4.70%	-5.09%	-17.59%	-30.82%	-22.34%	-45.50%
Return on Common Equity (ROCE)	19.39%	-15.42%	-28.39%	-51.49%	-36.27%	172.63%
Return on Equity Simple (ROE_SIMPLE)	15.51%	-18.24%	-19.34%	-65.16%	-27.67%	-61.39%
Net Operating Profit after Tax (NOPAT)	37	-20	-22	-28	-18	-21
NOPAT Margin	8.42%	-8.32%	-23.55%	-91.20%	-72.03%	-87.79%
Net Nonoperating Expense Percent (NNEP)	1.20%	-31.64%	-14.24%	-22.42%	-14.95%	-27.56%
Return On Investment Capital (ROIC_SIMPLE)	5.04%	-3.13%	-8.94%	-	-	-
Cost of Revenue to Revenue	40.64%	36.23%	30.16%	30.08%	35.12%	41.27%
SG&A Expenses to Revenue	38.19%	49.48%	74.79%	126.51%	94.34%	99.97%
R&D to Revenue	12.68%	26.18%	28.69%	73.70%	73.45%	84.18%
Operating Expenses to Revenue	50.86%	75.66%	103.48%	200.21%	167.79%	184.15%
Earnings before Interest and Taxes (EBIT)	50	-16	-32	-40	-25	-29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	70	-7.70	-29	-37	-23	-28
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	9.15	18.78	10.52	7.84	5.20	7.20
Price to Tangible Book Value (P/TBV)	9.74	20.97	10.52	7.84	5.20	7.20
Price to Revenue (P/Rev)	4.74	10.66	21.08	17.58	21.08	16.67
Price to Earnings (P/E)	59.01	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.69%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.65	10.81	40.72	44.80	34.83	42.79
Enterprise Value to Revenue (EV/Rev)	5.13	11.13	19.56	15.69	17.53	14.70
Enterprise Value to EBITDA (EV/EBITDA)	32.38	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	45.13	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	60.95	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	46.42	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	2.23	3.69	0.31	0.52	0.33	0.62
Long-Term Debt to Equity	2.23	3.69	0.31	0.52	0.33	0.62
Financial Leverage	0.78	-0.10	-0.78	-0.86	-0.87	-0.85
Leverage Ratio	4.13	3.03	1.61	1.67	1.62	3.01
Compound Leverage Factor	2.94	5.09	1.80	1.83	1.88	3.46
Debt to Total Capital	69.02%	78.68%	23.85%	34.15%	25.01%	38.45%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	69.02%	78.68%	23.85%	34.15%	25.01%	38.45%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	30.98%	21.32%	76.15%	65.85%	74.99%	61.55%
Debt to EBITDA	7.28	-65.72	-2.05	-0.95	-1.54	-1.21
Net Debt to EBITDA	2.47	-14.46	4.99	1.54	4.04	1.65
Long-Term Debt to EBITDA	7.28	-65.72	-2.05	-0.95	-1.54	-1.21
Debt to NOPAT	13.70	-25.17	-2.67	-1.28	-1.88	-1.65
Net Debt to NOPAT	4.65	-5.54	6.47	2.07	4.93	2.25
Long-Term Debt to NOPAT	13.70	-25.17	-2.67	-1.28	-1.88	-1.65
Altman Z-Score	2.77	2.76	11.69	0.26	3.77	0.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	381.23%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	8.30	9.30	10.66	5.11	12.36	6.21
Quick Ratio	7.25	8.34	9.67	4.23	11.15	5.41
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-116	-224	-56	-25	-23	0.00
Operating Cash Flow to CapEx	37.61%	-8.58%	-384.79%	-820.23%	-6,651.65%	-19,567.27%
Free Cash Flow to Firm to Interest Expense	-8.02	-20.74	-15.11	-6.53	-5.84	0.00
Operating Cash Flow to Interest Expense	3.39	-1.21	-12.30	-7.45	-7.59	-7.42
Operating Cash Flow Less CapEx to Interest Expense	-5.62	-15.28	-15.49	-8.36	-7.71	-7.45
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.58	0.49	0.45	0.21	0.20	0.32
Accounts Receivable Turnover	5.47	5.30	5.57	4.73	3.82	4.72
Inventory Turnover	3.95	2.70	1.59	0.68	0.78	0.95
Fixed Asset Turnover	1.92	2.50	6.43	4.15	5.37	5.71
Accounts Payable Turnover	15.60	10.90	5.64	2.32	2.13	1.63
Days Sales Outstanding (DSO)	66.67	68.87	65.50	77.18	95.55	77.29
Days Inventory Outstanding (DIO)	92.33	135.19	229.62	537.16	469.22	383.94
Days Payable Outstanding (DPO)	23.40	33.48	64.69	157.52	171.33	224.20
Cash Conversion Cycle (CCC)	135.60	170.58	230.43	456.82	393.44	237.03
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	401	249	45	11	13	8.11
Invested Capital Turnover	1.36	1.65	3.37	2.57	2.44	2.91
Increase / (Decrease) in Invested Capital	153	204	34	-2.31	4.80	0.00
Enterprise Value (EV)	2,265	2,688	1,828	475	450	347
Market Capitalization	2,093	2,577	1,970	532	541	393
Book Value per Share	$6.81	$4.20	$5.87	$2.44	$3.83	$2.58
Tangible Book Value per Share	$6.40	$3.76	$5.87	$2.44	$3.83	$2.58
Total Capital	738	643	246	103	139	89
Total Debt	509	506	59	35	35	34
Total Long-Term Debt	509	506	59	35	35	34
Net Debt	173	111	-142	-57	-91	-47
Capital Expenditures (CapEx)	130	152	12	3.52	0.46	0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	101	61	27	3.02	9.25	3.20
Debt-free Net Working Capital (DFNWC)	437	456	229	95	135	84
Net Working Capital (NWC)	437	456	229	95	135	84
Net Nonoperating Expense (NNE)	1.70	4.92	14	17	10	13
Net Nonoperating Obligations (NNO)	173	111	-142	-57	-91	-47
Total Depreciation and Amortization (D&A)	20	8.18	3.86	3.17	2.21	1.02
Debt-free, Cash-free Net Working Capital to Revenue	22.80%	25.21%	29.37%	9.96%	36.06%	13.55%
Debt-free Net Working Capital to Revenue	99.04%	188.61%	244.63%	315.47%	526.10%	355.39%
Net Working Capital to Revenue	99.04%	188.61%	244.63%	315.47%	526.10%	355.39%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.07	($0.77)	($1.23)	($1.60)	($1.16)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	33.23M	32.52M	29.56M	27.62M	27.37M	0.00
Adjusted Diluted Earnings per Share	$1.01	($0.77)	($1.23)	($1.60)	($1.16)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	35.22M	32.52M	29.56M	27.62M	27.37M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.16)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.66M	32.72M	32.20M	27.96M	24.70M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	37	-20	-22	-28	-18	-21
Normalized NOPAT Margin	8.42%	-8.32%	-23.55%	-91.20%	-72.03%	-87.79%
Pre Tax Income Margin	8.10%	-11.04%	-38.70%	-145.99%	-112.00%	-141.95%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	3.48	-1.47	-8.71	-10.40	-6.21	-6.70
NOPAT to Interest Expense	2.58	-1.86	-5.91	-7.12	-4.63	-4.76
EBIT Less CapEx to Interest Expense	-5.52	-15.54	-11.90	-11.31	-6.32	-6.74
NOPAT Less CapEx to Interest Expense	-6.43	-15.94	-9.10	-8.03	-4.75	-4.80
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-14.45%

This table displays calculated financial ratios and metrics derived from TransMedics Group's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	48.21%	49.83%	63.72%	117.87%	133.07%	158.72%	158.65%	155.66%	161.68%	224.52%	378.27%
EBITDA Growth	78.75%	46.66%	160.80%	598.49%	8,315.79%	351.15%	-275.13%	130.41%	97.21%	59.65%	49.01%
EBIT Growth	88.46%	41.40%	133.69%	934.49%	1,142.44%	231.16%	-252.55%	114.48%	84.01%	51.22%	44.71%
NOPAT Growth	116.13%	212.23%	119.64%	2,078.90%	935.98%	157.24%	-411.09%	90.70%	77.70%	40.16%	52.72%
Net Income Growth	110.56%	70.11%	116.58%	1,318.18%	562.71%	159.99%	-242.34%	91.31%	75.04%	46.95%	42.71%
EPS Growth	100.00%	58.33%	115.38%	1,266.67%	537.50%	163.16%	-212.00%	92.68%	78.95%	57.78%	46.81%
Operating Cash Flow Growth	16.89%	136.79%	199.84%	543.18%	60.34%	305.80%	51.91%	36.19%	52.94%	39.31%	-52.75%
Free Cash Flow Firm Growth	50.15%	28.26%	-2.44%	-687.36%	-844.11%	-414.89%	-314.15%	-3.91%	-11.95%	-594.26%	-457.36%
Invested Capital Growth	47.44%	61.41%	89.64%	394.88%	464.17%	453.80%	316.04%	88.18%	79.36%	323.52%	357.79%
Revenue Q/Q Growth	18.02%	11.83%	-4.85%	18.02%	19.31%	22.19%	26.62%	26.26%	32.44%	22.16%	25.15%
EBITDA Q/Q Growth	123.36%	24.55%	-36.00%	0.40%	83.27%	151.63%	-835.21%	1,280.97%	94.40%	22.88%	40.40%
EBIT Q/Q Growth	185.39%	34.32%	-50.16%	-1.34%	114.13%	132.00%	-1,630.43%	199.41%	73.06%	13.99%	37.13%
NOPAT Q/Q Growth	211.53%	117.67%	-68.96%	2.66%	350.06%	113.69%	-3,027.48%	56.63%	69.18%	-22.28%	43.11%
Net Income Q/Q Growth	274.54%	62.64%	-65.43%	-0.02%	202.58%	115.86%	-2,439.66%	62.03%	60.77%	9.51%	35.56%
EPS Q/Q Growth	268.42%	58.33%	-65.71%	0.00%	191.67%	115.38%	-2,500.00%	62.50%	57.89%	24.00%	39.02%
Operating Cash Flow Q/Q Growth	-114.52%	186.76%	-73.34%	848.70%	-141.37%	220.91%	-18.35%	33.00%	-114.65%	71.75%	-57.05%
Free Cash Flow Firm Q/Q Growth	14.27%	19.75%	29.45%	-2.71%	-23.37%	-14.59%	-442.26%	-23.16%	32.72%	7.83%	-36.06%
Invested Capital Q/Q Growth	16.20%	3.32%	15.96%	5.90%	27.21%	21.39%	202.61%	20.73%	24.87%	-8.80%	36.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.47%	59.21%	55.94%	60.59%	61.91%	59.04%	61.21%	70.03%	69.23%	65.99%	70.53%
EBITDA Margin	25.27%	13.35%	11.99%	17.83%	20.95%	13.64%	-32.28%	5.56%	-0.59%	-14.05%	-22.26%
Operating Margin	19.12%	7.11%	3.61%	10.94%	12.83%	3.21%	-42.65%	-1.73%	-5.03%	-21.61%	-21.59%
EBIT Margin	21.00%	8.68%	7.23%	13.80%	16.51%	9.20%	-35.13%	2.91%	-3.69%	-18.15%	-25.78%
Profit (Net Income) Margin	17.89%	5.64%	3.88%	10.67%	12.59%	4.97%	-38.27%	-1.91%	-6.34%	-21.42%	-28.91%
Tax Burden Percent	96.27%	98.11%	99.32%	100.34%	98.42%	104.35%	94.40%	102.14%	100.42%	100.28%	100.26%
Interest Burden Percent	88.52%	66.18%	53.99%	77.03%	77.50%	51.73%	115.38%	-64.26%	171.12%	117.69%	111.89%
Effective Tax Rate	3.73%	1.89%	0.68%	-0.34%	1.58%	-4.35%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	22.97%	9.48%	4.84%	19.57%	20.13%	5.51%	-45.10%	-3.52%	-9.60%	-50.95%	-36.16%
ROIC Less NNEP Spread (ROIC-NNEP)	22.56%	8.33%	5.09%	18.51%	19.86%	-2.95%	-26.57%	-2.73%	-8.18%	-48.97%	-32.72%
Return on Net Nonoperating Assets (RNNOA)	18.90%	6.47%	3.89%	3.73%	1.14%	0.28%	5.10%	1.29%	5.35%	38.32%	25.35%
Return on Equity (ROE)	41.87%	15.95%	8.73%	23.30%	21.27%	5.79%	-40.00%	-2.24%	-4.25%	-12.62%	-10.80%
Cash Return on Invested Capital (CROIC)	-25.22%	-35.55%	-51.30%	-133.57%	-145.12%	-152.52%	-143.49%	-81.89%	-95.55%	-202.91%	-212.29%
Operating Return on Assets (OROA)	13.13%	5.08%	3.93%	6.83%	9.70%	4.52%	-13.98%	1.09%	-2.14%	-8.23%	-9.11%
Return on Assets (ROA)	11.19%	3.30%	2.11%	5.28%	7.40%	2.44%	-15.23%	-0.71%	-3.68%	-9.72%	-10.22%
Return on Common Equity (ROCE)	41.87%	15.95%	8.73%	23.30%	21.27%	5.79%	-40.00%	-2.24%	-4.25%	-12.62%	-10.80%
Return on Equity Simple (ROE_SIMPLE)	18.38%	0.00%	15.55%	1.58%	-6.39%	0.00%	-28.29%	-12.25%	-14.69%	0.00%	-22.45%
Net Operating Profit after Tax (NOPAT)	26	8.48	3.90	13	12	2.72	-20	-0.63	-1.46	-4.75	-3.88
NOPAT Margin	18.41%	6.97%	3.58%	10.98%	12.62%	3.35%	-29.86%	-1.21%	-3.52%	-15.12%	-15.11%
Net Nonoperating Expense Percent (NNEP)	0.41%	1.14%	-0.25%	1.06%	0.27%	8.46%	-18.53%	-0.79%	-1.42%	-1.98%	-3.43%
Return On Investment Capital (ROIC_SIMPLE)	3.40%	1.15%	-	-	-	0.42%	-	-	-	-1.93%	-
Cost of Revenue to Revenue	38.53%	40.79%	44.06%	39.41%	38.09%	40.96%	38.79%	29.97%	30.77%	34.01%	29.47%
SG&A Expenses to Revenue	30.39%	38.57%	39.22%	37.53%	37.34%	42.58%	46.14%	55.95%	60.12%	69.25%	65.61%
R&D to Revenue	11.96%	13.54%	13.12%	12.12%	11.75%	13.26%	57.72%	15.80%	14.13%	18.35%	26.51%
Operating Expenses to Revenue	42.35%	52.10%	52.34%	49.65%	49.09%	55.83%	103.86%	71.76%	74.25%	87.59%	92.12%
Earnings before Interest and Taxes (EBIT)	30	11	7.86	16	16	7.47	-23	1.53	-1.53	-5.69	-6.62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	36	16	13	20	20	11	-21	2.92	-0.25	-4.41	-5.72
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.50	9.15	24.95	26.13	15.14	18.78	14.13	18.83	12.66	10.52	6.24
Price to Tangible Book Value (P/TBV)	8.96	9.74	26.70	28.17	16.63	20.97	15.90	18.83	12.66	10.52	6.24
Price to Revenue (P/Rev)	4.64	4.74	13.06	13.83	8.13	10.66	9.31	18.10	20.47	21.08	16.34
Price to Earnings (P/E)	46.27	59.01	160.47	1,653.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.16%	1.69%	0.62%	0.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.29	5.65	13.95	15.25	8.13	10.81	9.11	39.25	41.06	40.72	21.01
Enterprise Value to Revenue (EV/Rev)	5.05	5.13	13.50	14.23	8.66	11.13	9.72	17.58	19.32	19.56	14.41
Enterprise Value to EBITDA (EV/EBITDA)	28.68	32.38	83.60	168.54	200.26	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	38.31	45.13	114.99	321.21	1,562.75	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	48.00	60.95	172.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	49.91	46.42	144.64	215.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.92	2.23	2.42	2.67	3.18	3.69	4.00	3.48	0.31	0.31	0.35
Long-Term Debt to Equity	1.92	2.23	2.42	2.67	3.18	3.69	4.00	3.48	0.31	0.31	0.35
Financial Leverage	0.84	0.78	0.76	0.20	0.06	-0.10	-0.19	-0.47	-0.65	-0.78	-0.77
Leverage Ratio	3.67	4.13	4.38	4.32	2.87	3.03	3.07	4.12	1.63	1.61	1.52
Compound Leverage Factor	3.25	2.73	2.37	3.33	2.23	1.57	3.54	-2.65	2.79	1.90	1.71
Debt to Total Capital	65.70%	69.02%	70.78%	72.78%	76.07%	78.68%	79.99%	77.66%	23.39%	23.85%	26.09%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	65.70%	69.02%	70.78%	72.78%	76.07%	78.68%	79.99%	77.66%	23.39%	23.85%	26.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	34.30%	30.98%	29.22%	27.22%	23.93%	21.32%	20.01%	22.34%	76.61%	76.15%	73.91%
Debt to EBITDA	5.94	7.28	7.85	16.76	39.49	-65.72	-21.80	-67.58	-2.95	-2.05	-1.89
Net Debt to EBITDA	2.33	2.47	2.75	4.79	12.21	-14.46	-3.38	10.38	6.84	4.99	3.95
Long-Term Debt to EBITDA	5.94	7.28	7.85	16.76	39.49	-65.72	-21.80	-67.58	-2.95	-2.05	-1.89
Debt to NOPAT	9.93	13.70	16.17	-311.94	-50.94	-25.17	-18.95	-47.07	-3.48	-2.67	-2.63
Net Debt to NOPAT	3.89	4.65	5.68	-89.08	-15.75	-5.54	-2.94	7.23	8.08	6.47	5.50
Long-Term Debt to NOPAT	9.93	13.70	16.17	-311.94	-50.94	-25.17	-18.95	-47.07	-3.48	-2.67	-2.63
Altman Z-Score	2.99	2.61	5.82	5.61	2.83	2.87	1.89	3.35	14.51	12.01	6.87
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.10	8.30	8.20	9.37	9.72	9.30	10.93	20.70	9.14	10.66	12.11
Quick Ratio	8.13	7.25	7.00	8.17	8.60	8.34	9.93	19.67	8.17	9.67	10.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-124	-144	-180	-255	-248	-201	-175	-32	-26	-39	-42
Operating Cash Flow to CapEx	-10.56%	144.52%	14.23%	108.23%	-7.78%	19.86%	-6.38%	-420.51%	-934.30%	-145.98%	-487.44%
Free Cash Flow to Firm to Interest Expense	-35.72	-40.38	-49.68	-70.29	-68.91	-55.75	-48.86	-12.91	-24.07	-38.76	-53.81
Operating Cash Flow to Interest Expense	-0.82	5.51	1.90	7.10	-0.95	2.30	-1.91	-2.32	-7.94	-4.01	-18.15
Operating Cash Flow Less CapEx to Interest Expense	-8.64	1.70	-11.43	0.54	-13.23	-9.30	-31.92	-2.87	-8.79	-6.75	-21.87
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.58	0.54	0.50	0.59	0.49	0.40	0.37	0.58	0.45	0.35
Accounts Receivable Turnover	4.36	5.47	5.32	5.58	4.93	5.30	4.64	4.99	4.73	5.57	5.48
Inventory Turnover	4.31	3.95	3.56	3.56	3.08	2.70	2.24	1.95	1.83	1.59	1.21
Fixed Asset Turnover	1.86	1.92	1.99	2.88	2.54	2.50	2.57	8.36	7.64	6.43	6.10
Accounts Payable Turnover	19.97	15.60	12.56	14.05	16.47	10.90	8.16	7.34	10.24	5.64	7.01
Days Sales Outstanding (DSO)	83.72	66.67	68.61	65.46	74.10	68.87	78.67	73.09	77.12	65.50	66.60
Days Inventory Outstanding (DIO)	84.78	92.33	102.40	102.57	118.53	135.19	162.80	187.42	199.55	229.62	302.20
Days Payable Outstanding (DPO)	18.28	23.40	29.06	25.97	22.16	33.48	44.72	49.74	35.63	64.69	52.07
Cash Conversion Cycle (CCC)	150.22	135.60	141.95	142.06	170.48	170.58	196.75	210.77	241.04	230.43	316.74
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	466	401	388	335	316	249	205	68	56	45	49
Invested Capital Turnover	1.25	1.36	1.35	1.78	1.60	1.65	1.51	2.92	2.73	3.37	2.39
Increase / (Decrease) in Invested Capital	150	153	184	267	260	204	156	32	25	34	38
Enterprise Value (EV)	2,465	2,265	5,416	5,106	2,571	2,688	1,865	2,656	2,302	1,828	1,034
Market Capitalization	2,265	2,093	5,237	4,961	2,414	2,577	1,787	2,734	2,438	1,970	1,173
Book Value per Share	$7.91	$6.81	$6.29	$5.77	$4.87	$4.20	$3.88	$4.46	$5.98	$5.87	$6.69
Tangible Book Value per Share	$7.51	$6.40	$5.88	$5.35	$4.43	$3.76	$3.44	$4.46	$5.98	$5.87	$6.69
Total Capital	776	738	718	698	666	643	632	650	251	246	254
Total Debt	510	509	509	508	507	506	505	505	59	59	66
Total Long-Term Debt	510	509	509	508	507	506	505	505	59	59	66
Net Debt	200	173	178	145	157	111	78	-78	-137	-142	-139
Capital Expenditures (CapEx)	27	14	48	24	44	42	108	1.38	0.93	2.76	2.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	140	101	102	92	88	61	61	48	38	27	25
Debt-free Net Working Capital (DFNWC)	450	437	432	455	438	456	488	631	233	229	230
Net Working Capital (NWC)	450	437	432	455	438	456	488	631	233	229	230
Net Nonoperating Expense (NNE)	0.74	1.62	-0.32	0.36	0.03	-1.31	5.59	0.37	1.17	1.97	3.55
Net Nonoperating Obligations (NNO)	200	173	178	145	157	111	78	-78	-137	-142	-139
Total Depreciation and Amortization (D&A)	6.14	5.68	5.18	4.60	4.30	3.61	1.89	1.39	1.29	1.29	0.90
Debt-free, Cash-free Net Working Capital to Revenue	28.71%	22.80%	25.51%	25.70%	29.59%	25.21%	31.55%	32.06%	31.66%	29.37%	34.75%
Debt-free Net Working Capital to Revenue	92.23%	99.04%	107.81%	126.81%	147.54%	188.61%	254.20%	417.43%	195.66%	244.63%	320.41%
Net Working Capital to Revenue	92.23%	99.04%	107.81%	126.81%	147.54%	188.61%	254.20%	417.43%	195.66%	244.63%	320.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.76	$0.20	$0.13	$0.37	$0.37	$0.12	($0.78)	($0.03)	($0.08)	($0.19)	($0.25)
Adjusted Weighted Average Basic Shares Outstanding	33.72M	33.23M	33.44M	33.12M	32.76M	32.52M	32.61M	32.55M	32.26M	29.56M	30.23M
Adjusted Diluted Earnings per Share	$0.70	$0.19	$0.12	$0.35	$0.35	$0.12	($0.78)	($0.03)	($0.08)	($0.19)	($0.25)
Adjusted Weighted Average Diluted Shares Outstanding	39.91M	35.22M	35.68M	35.29M	34.68M	32.52M	32.61M	32.55M	32.26M	29.56M	30.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.83M	33.66M	33.56M	33.36M	32.94M	32.72M	32.65M	32.63M	32.55M	32.20M	31.92M
Normalized Net Operating Profit after Tax (NOPAT)	26	8.48	3.90	8.76	12	1.82	-20	-0.63	-1.46	-4.75	-3.88
Normalized NOPAT Margin	18.41%	6.97%	3.58%	7.66%	12.62%	2.24%	-29.86%	-1.21%	-3.52%	-15.12%	-15.11%
Pre Tax Income Margin	18.58%	5.75%	3.90%	10.63%	12.80%	4.76%	-40.54%	-1.87%	-6.32%	-21.36%	-28.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.71	2.96	2.17	4.35	4.44	2.07	-6.50	0.61	-1.41	-5.65	-8.41
NOPAT to Interest Expense	7.63	2.37	1.08	3.46	3.40	0.75	-5.52	-0.25	-1.34	-4.71	-4.93
EBIT Less CapEx to Interest Expense	0.90	-0.85	-11.15	-2.20	-7.83	-9.53	-36.51	0.06	-2.26	-8.40	-12.13
NOPAT Less CapEx to Interest Expense	-0.18	-1.44	-12.25	-3.09	-8.88	-10.85	-35.53	-0.80	-2.19	-7.46	-8.65
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About TransMedics Group's Financials

When does TransMedics Group's fiscal year end?

According to the most recent income statement we have on file, TransMedics Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has TransMedics Group's net income changed over the last 5 years?

TransMedics Group's net income appears to be on a downward trend, with a most recent value of $35.46 million in 2024, falling from -$33.55 million in 2019. The previous period was -$25.03 million in 2023. See TransMedics Group's forecast for analyst expectations on what’s next for the company.

What is TransMedics Group's operating income?

TransMedics Group's total operating income in 2024 was $37.50 million, based on the following breakdown:

Total Gross Profit: $262.08 million
Total Operating Expenses: $224.59 million

How has TransMedics Group revenue changed over the last 5 years?

Over the last 5 years, TransMedics Group's total revenue changed from $23.60 million in 2019 to $441.54 million in 2024, a change of 1,770.6%.

How much debt does TransMedics Group have?

TransMedics Group's total liabilities were at $575.47 million at the end of 2024, a 1.2% increase from 2023, and a 1,101.9% increase since 2018.

How much cash does TransMedics Group have?

In the past 6 years, TransMedics Group's cash and equivalents has ranged from $20.09 million in 2019 to $394.81 million in 2023, and is currently $336.65 million as of their latest financial filing in 2024.

How has TransMedics Group's book value per share changed over the last 5 years?

Over the last 5 years, TransMedics Group's book value per share changed from 2.58 in 2019 to 6.81 in 2024, a change of 163.8%.

Related Companies

This page (NASDAQ:TMDX) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Financials

Frequently Asked Questions About TransMedics Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Financials

Annual Income Statements for TransMedics Group

Quarterly Income Statements for TransMedics Group

Annual Cash Flow Statements for TransMedics Group

Quarterly Cash Flow Statements for TransMedics Group

Annual Balance Sheets for TransMedics Group

Quarterly Balance Sheets for TransMedics Group

Annual Metrics And Ratios for TransMedics Group

Quarterly Metrics And Ratios for TransMedics Group

Frequently Asked Questions About TransMedics Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools